Platelet activating factor as a mediator and therapeutic approach in bronchial asthma
Platelet activating factor as a mediator and therapeutic approach in bronchial asthma
复制标题
DOI：
10.1007/s10753-007-9056-9
复制
发表时间：
2008-04-01
期刊：
影响因子：
5.1
通讯作者：
Rogala, B.
中科院分区：
文献类型：
--
作者：
Kasperska-Zajac, A.;Brzoza, Z.;Rogala, B.
血小板活化因子(PAF)是一种有效的磷脂介质，参与过敏反应和慢性炎症性疾病，包括哮喘。PAF既可以直接作为趋化因子发挥作用，也可以通过释放其他炎症因子间接发挥作用。除了已知的激活血小板的强大能力外，PAF还影响与哮喘有关的其他免疫和炎症细胞功能，这可能在哮喘的发病机制中发挥重要作用。此外，应用PAF可以模拟哮喘时观察到的一些异常，包括支气管收缩、支气管高反应性和气体交换障碍，这些异常可能是由白三烯作为某些PAF效应的二级介质所介导的。因此，人们对PAF在人类哮喘中的作用产生了广泛的兴趣，并一直在努力寻找能够彻底抑制PAF在疾病中的作用的药物。令人惊讶的是，PAF受体拮抗剂还没有明确证明它们的临床益处。似乎联合阻断PAF效应和其他参与哮喘的介质是提高临床疗效的一种方法，也是控制疾病炎症的一种有趣的方法。这篇综述将集中在两个主要问题：PAF和PAF拮抗剂在哮喘中的作用。
Platelet activating factor (PAF) is a potent phospholipid mediator involved in anaphylaxis and chronic inflammatory disorders, including bronchial asthma. PAF is able to act both, directly as a chemotactic factor and indirectly through the release of other inflammatory agents. Apart from its known potent ability to activate platelets, PAF influences other immune and inflammatory cells function involved in asthma, which may be of importance in the pathogenesis of the disease. In addition, PAF administration can mimic some of abnormalities observed in asthma, including bronchoconstriction, bronchial hyper responsiveness, and gas exchange impairment, which may be mediated by leukotrienes acting as secondary mediators of some PAF effects. Therefore, there has been an extensive interest in the role of PAF in human asthma and major efforts have been continued to discover drugs acting thorough inhibition of PAF effects in the disease. Surprisingly, PAF receptor antagonists have not clearly proven their clinical benefits. It may appear that the combined blockage of PAF effects and other mediators involved in asthma is a way to improve clinical efficacy and also an interesting approach to control inflammation in the disease. This review will focus on two main issues: the role of PAF and PAF antagonists in asthma.